

REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

caspofungin

Effective Date: Nov 7 2018 CLASSIFICATION OTHER NAMES

Revised Date: Nov 2024 OTHER NAMES

Cancidas OTHER NAMES

1 of 2

ADMINISTRATION POLICY:

IV Bolus - Not recommended

IV Intermittent - May be administered by a nurse MINI-BAG PLUS COMPATIBLE

IM Injection - Not recommended
Subcutaneous - Not recommended

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as: 50 and 70 mg vials of lyophilized powder.

CANCIDAS (Merck brand) and Juno brand: Refrigerate. Bring vial to room temperature before reconstituting.

Fresenius Kabi brand: Store at room temperature.

Reconstitution:

Strength	Volume of sterile water for injection*	Final concentration	Final volume
50 mg	10.5 mL	5 mg/mL	10.5 mL
70 mg	10.5 mL	7 mg/mL	10.5 mL

IV Intermittent: Administer over 1 hour (for 150 mg dose, administer over 2 hours)

Dose	Dose Preferred Diluent Volumes Bag size	Fluid Restricted Patient	
	NaCl 0.9%		
	MINI BAG PLUS COMPATIBLE (50 & 70 mg vial)		
50 mg	250 mL	100 mL	
70 mg	250 mL	N/A	
150 mg	250 mL	N/A	

DOSAGE:

Usual: 70 mg IV load on day 1; then 50 mg IV once daily

Maximum rate: over 1 hour **Maximum concentration:** 0.5 mg/mL

Maximum single dose: 150 mg **Maximum daily dose:** 150 mg

STABILITY/COMPATIBILITY:

Stability of reconstituted solution: 1 hour at room temperature

Stability of Final Admixture: 24 hours refrigerated or room temperature

Compatibility: Compatible with normal saline, Lactated Ringer

Incompatible with dextrose



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

caspofungin

Effective Date: Nov 7 2018 CLASSIFICATION OTHER NAMES PAGE Antifungal Cancidas 2 of 2 **Revised Date:** Nov 2024

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Rapid infusions may produce facial swelling, itching, vasodilation, hypotension and shock (anaphylactoid)
- Local reactions: phlebitis, thrombophlebitis, pain on injection, rash, pruritis
- GI: diarrhea, nausea, vomiting
- CNS: fever, headache, chills
- Hematologic: decreased hemoglobin, decreased hematocrit, decreased WBC, anemia
- Hepatic: elevated liver function tests (especially ALT, AST, alkaline phosphatase), hyperbilirubinemia
- Renal: Increased serum creatinine
- Respiratory: Failure, cough, pneumonia

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- No dosage adjustment required in renal dysfunction
- Dosage adjustment may be required in hepatic dysfunction